Alison G Kartush1, Jane K Schumacher2, Rachna Shah1, Monica O Patadia1. 1. 1 Department of Otolaryngology, Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois. 2. 2 Department of Internal Medicine. Affiliate clinician: Loyola University Medical Center, Maywood, Illinois.
Abstract
BACKGROUND: Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population. OBJECTIVE: The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials. METHODS: A comprehensive review of literature and clinical trials-both recently completed and ongoing-was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients-including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme. RESULTS: Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed. CONCLUSION: These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.
BACKGROUND:Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population. OBJECTIVE: The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitispatients by reviewing literature and clinical trials. METHODS: A comprehensive review of literature and clinical trials-both recently completed and ongoing-was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitispatients-including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme. RESULTS: Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed. CONCLUSION: These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.
Authors: Andras Bikov; Ipek Kivilcim Oğuzülgen; Ilaria Baiardini; Marco Contoli; Alexander Emelyanov; Omar Fassio; Juan Carlos Ivancevich; Igor Kaidashev; Krzysztof Kowal; Marina Labor; Lies Lahousse; Stefan Mihaicuta; Silviya Novakova; Alicia Padilla Galo; Alexander Simidchiev; Angelica Tiotiu; Ignacio J Ansotegui; Jonathan A Bernstein; Louis Philippe Boulet; Giorgio Walter Canonica; Lawrence Dubuske; Nelson Rosario; Pierachille Santus; Fulvio Braido Journal: World Allergy Organ J Date: 2020-07-31 Impact factor: 4.084
Authors: Hyun Sil Lee; Anabel Gonzalez-Gil; Virginia Drake; T August Li; Ronald L Schnaar; Jean Kim Journal: Glycobiology Date: 2021-09-09 Impact factor: 4.313
Authors: Nyssa F Farrell; Jess C Mace; David A Sauer; Andrew J Thomas; Mathew Geltzeiler; Kara Y Detwiller; Timothy L Smith Journal: Am J Rhinol Allergy Date: 2021-01-11 Impact factor: 2.467
Authors: Luciana Kase Tanno; Pascal Demoly; Bryan Martin; Jonathan Berstein; Mario Morais-Almeida; Michael Levin; Alessandro Fiocchi; Mario Sánchez-Borges; Luis R Caraballo; Gary Wong; José Antonio Ortega-Martell; Philip Rouadi; Anahí Yáñez; Liang Lu Wang; David B Peden; Manana Chikhladze; Sandra N González-Díaz; Jean-François Fontaine; James Sublett; Yoon-Seok Chang; Giovanni Passalacqua; Ignacio J Ansotegui; Motohiro Ebisawa; Gianenrico Senna; Marco Caminati Journal: World Allergy Organ J Date: 2021-01-31 Impact factor: 4.084